Drug Trial Radar · NCT02405442
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Apr 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
187
Actual
Start
Apr 30, 2015
Primary completion
Nov 30, 2016
Study completion Dec 22, 2016
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Apr 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will primarily evaluate the safety and efficacy of andecaliximab in adults with active Crohn's disease. The study will consist of a Double-Blind Phase of 8 weeks followed by an Open-Label Extension. Participants who complete the Double-Blind Phase will be eligible to enroll in the optional Open-Label Extension for an additional 44 weeks. Participants who complete Week 52 assessments will be eligible to enter the Extended Treatment Phase to continue treatment with andecaliximab for an additional 156 weeks.
Conditions
- Crohn's Disease
Interventions
AndecaliximabDrug
Andecaliximab administered via subcutaneous (SC) injection
PlaceboDrug
Placebo to match andecaliximab administered via SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8) at Week 8 of the Double-Blind PhaseTime frame: Week 8
- Percentage of Participants Achieving Endoscopic Response (≥ 50% Reduction From Baseline SES-CD) at Week 8 of the Double-Blind PhaseTime frame: Week 8
Locations
74 sites in 13 countries. Site status is shown where the registry gives one.
Digestive Health Specialists of The Southeast
Dothan, Alabama
Mayo Clinic
Scottsdale, Arizona
Cedars Sinai Medical Center
Los Angeles, California
South Denver Gastroenterology
Lone Tree, Colorado
University of Miami
Miami, Florida
Gastroenterology Group Of Naples
Naples, Florida
Gastroenterology Associates Of Central Georgia, LLC
Macon, Georgia
Medical Diagnostic Center (MDC)-Indiana University (IU) Health University Hospital
Indianapolis, Indiana
Iowa Digestive Disease Center
Clive, Iowa
Cotton-O'Neil Clinical Research Center, Digestive Health
Topeka, Kansas
Delta Research Partners
Monroe, Louisiana
Louisiana Research Center
Shreveport, Louisiana
University of Michigan
Ann Arbor, Michigan
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
AGA Clinical Research Associates, LLC
Egg Harbor, New Jersey
Columbia University Medical Center/ New York Presbyterian
New York, New York
Premier Medical Group Of The Hudson Valley
Poughkeepsie, New York
Mayo Clinic Rochester
Rochester, New York
Asheville Gastroenterology Associates
Asheville, North Carolina
Consultants For Clinical Research
Cincinnati, Ohio
Great Lakes Gastroenterology
Mentor, Ohio
Gastro One
Germantown, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Clinical Research Institute
Arlington, Texas
Ertan Digestive Disease Center of Excellence, UTH/MH-TMC
Houston, Texas
Gastroenterology Research of San Antonio
San Antonio, Texas
Gastroenterology Associates Of Tidewater
Chesapeake, Virginia
Digestive and Liver Disease Specialists
Norfolk, Virginia
Mcguire Dvamc
Richmond, Virginia
University of Washington Medical Center
Seattle, Washington
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Footscray Hospital
Footscray, Victoria, Australia
Gastroenterology/Colorectal Medicine & Genetics
Melbourne, Victoria, Australia
Percuro Clinical Research Ltd.
Victoria, Canada
Percuro Clinical Research Ltd.
Victoria, British Columbia, Canada
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.